Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer

F Cappuzzo, A Morabito, N Normanno, P Bidoli… - Lung Cancer, 2016 - Elsevier
Objectives Although patients with advanced non-small cell lung cancer (NSCLC) and an
activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR …
被引用次数：36 相关文章

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer

F Cappuzzo, A Morabito, N Normanno, P Bidoli… - Lung …, 2016 - lungcancerjournal.info
Objectives Although patients with advanced non-small cell lung cancer (NSCLC) and an
activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR …

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

F Cappuzzo, A Morabito, N Normanno… - Lung Cancer …, 2016 - europepmc.org
Objectives Although patients with advanced non-small cell lung cancer (NSCLC) and an
activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR …

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer

F Cappuzzo, A Morabito, N Normanno, P Bidoli… - Lung Cancer, 2016 - infona.pl
Although patients with advanced non-small cell lung cancer (NSCLC) and an activating
epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR-tyrosine …

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer

F Cappuzzo, A Morabito, N Normanno, P Bidoli… - LUNG CANCER, 2016 - air.unipr.it
Objectives Although patients with advanced non-small cell lung cancer (NSCLC) and an
activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR …

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer

F Cappuzzo, A Morabito, N Normanno, P Bidoli… - LUNG CANCER, 2016 - boa.unimib.it
Objectives Although patients with advanced non-small cell lung cancer (NSCLC) and an
activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR …

[引用][C] Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer

F Cappuzzo, A Morabito, N Normanno, P Bidoli… - Lung Cancer, 2016 - cir.nii.ac.jp
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small
cell lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer

F Cappuzzo, A Morabito… - Lung cancer …, 2016 - pubmed.ncbi.nlm.nih.gov
Objectives Although patients with advanced non-small cell lung cancer (NSCLC) and an
activating epidermal growth factor receptor (EGFR) mutation benefit from the use of EGFR …